Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 25Leukemia, Myeloid, Acute 24Lymphoma 22Breast Neoplasms 20Prostatic Neoplasms 15Colorectal Neoplasms 15Melanoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lung Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Neoplasm Metastasis 12Myelodysplastic Syndromes 12Lymphoma, Large B-Cell, Diffuse 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Triple Negative Breast Neoplasms 8Rectal Neoplasms 8Leukemia, Myelomonocytic, Chronic 8Carcinoma, Renal Cell 8Burkitt Lymphoma 8Sarcoma 7Lymphoma, Follicular 7Colonic Neoplasms 7Urinary Bladder Neoplasms 6Lymphoma, Non-Hodgkin 6Glioma 6Fallopian Tube Neoplasms 6Cholangiocarcinoma 6

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sinonasal Squamous Cell Carcinoma × Biopsy × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡